Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: Clinical implications for antifungal therapy

Journal of Infectious Diseases

Volumn 203, Issue 9, 2011, Pages 1324-1332

  Howard, Susan J ^a   Lestner, Jodi M ^a   Sharp, Andrew ^a   Gregson, Lea ^a   Goodwin, Joanne ^a   Slater, Joanne ^a   Majithiya, Jayesh B ^a   Warn, Peter A ^a   Hope, William W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; LUNG ASPERGILLOSIS; MALE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MICE; MODELS, THEORETICAL; TRIAZOLES;

EID: 79954610785     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir023     Document Type: Article

References (23)

1. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008;47:1176-84.
2. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010;18:195-204.
3. Hope WW, Drusano GL. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect 2009;15:602-12.
4. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85. (Pubitemid 41688982)
5. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001;45:857-69. (Pubitemid 32182037)
6. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12. (Pubitemid 44968977)
7. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59. (Pubitemid 46148777)
8. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47. (Pubitemid 46148776)
9. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15:1068-76.
10. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009;9:789-95.
11. Hope WW, Kruhlak MJ, Lyman CA, et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 2007;195:455-66. (Pubitemid 46146125)
12. Warn PA, Sharp A, Morrissey G, Denning DW. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and-resistant strains of Aspergillus fumigatus. Int J Antimicrob Agents 2010;35:146-51.
13. Cuenca-Estrella M, Arendrup MC, Chryssanthou E, et al. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2007;13:1018-22. (Pubitemid 47382259)
14. Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE Jr, Ibrahim AS. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2004;48:1908-11. (Pubitemid 38544412)
15. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource, 2009.
16. Leary R, Jelliffe R, Schumitzky A, van Guilder M. An adaptive grid, nonparametric approach to pharmacokinetic and dynamic (PK/PD) models. Proceedings, 14th IEEE Computer Society. Bethesda, MD, 2001;389-94. (Pubitemid 32806762)
17. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 2009;53:3453-61.
18. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010;48:1255-60.
19. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008;46:1412-22. (Pubitemid 351589942)
20. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009;115:355-62.
21. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010;54:860-5.
22. AbuTarif MA, Krishna G, Statkevich P. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin 2010;26:397-405.
23. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66. (Pubitemid 43190980)